(2)
BETHESDA, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) Gain Therapeutics, Inc. ( Gain ) today announced the addition of Dov Goldstein, M.D., Gwen Melincoff, Claude Nicaise, M.D. and Hans Peter Hasler as independent members to its Board of Directors. The new board additions will provide strategic guidance as the company focuses on identifying and optimizing allosteric binding sites that have never before been targeted to unlock new treatment options for difficult-to-treat disorders characterized by protein misfolding. In conjunction with the new additions, Dr. Lorenzo Leoni and Dr. Marianne Bjordal will be stepping down from Board. We are pleased to welcome such a distinguished group of board members at this pivotal time for Gain, said Eric Richman, Chief Executive Officer at Gain. Their decades of experience across the biopharmaceutical industry will be invaluable as we continue to advance our pipeline and determine how our proprietary Site-Directed Enzyme Enhancement Therapy (Se
(2)
NEW YORK, Jan. 31, 2021 /PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against Minerva Neurosciences, Inc. ( Minerva or the Company ) (NASDAQ: NERV) and certain of its officers. The class action, filed in United States District Court for the District of Massachusetts, and docketed under 21-cv-10051, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired securities between May 15, 2017 and November 30, 2020, inclusive (the Class Period ). This action is brought on behalf of the Class (as defined below) for violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act ), 15 U.S.C. §§ 78j(b) and 78t(a), and Rule 10b-5 promulgated thereunder by the SEC, 17 C.F.R. § 240.10b-5.
/PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against Minerva Neurosciences, Inc. ("Minerva" or the "Company") (NASDAQ:.
NEW YORK, NY / ACCESSWIRE / January 27, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ALERT NERV DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against .
Pawar Law GroupJanuary 25, 2021 GMT
NEW YORK, Jan. 25, 2021 (GLOBE NEWSWIRE) Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Minerva Neurosciences, Inc. (NASDAQ: NERV) from May 15, 2017 through November 30, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Minerva Neurosciences, Inc. investors under the federal securities laws.
To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.